Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Aalst, Belgien, 9300
- GSK Investigational Site
-
Brasschaat, Belgien, 2930
- GSK Investigational Site
-
Bruxelles, Belgien, 1200
- GSK Investigational Site
-
Gent, Belgien, 9000
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 1X5
- GSK Investigational Site
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 4G2
- GSK Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- GSK Investigational Site
-
-
-
-
-
Moscow, Den Russiske Føderation, 101000
- GSK Investigational Site
-
Moscow, Den Russiske Føderation, 111538
- GSK Investigational Site
-
Moscow, Den Russiske Føderation, 117152
- GSK Investigational Site
-
Perm, Den Russiske Føderation, 614107
- GSK Investigational Site
-
St. Petersburgh, Den Russiske Føderation, 192242
- GSK Investigational Site
-
-
-
-
-
Manila, Filippinerne, 1000
- GSK Investigational Site
-
Quezon, City, Filippinerne, 1104
- GSK Investigational Site
-
-
-
-
Alabama
-
Fairhope, Alabama, Forenede Stater, 36532
- GSK Investigational Site
-
Mobile, Alabama, Forenede Stater, 36608
- GSK Investigational Site
-
Montgomery, Alabama, Forenede Stater, 36106
- GSK Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- GSK Investigational Site
-
-
California
-
Arcadia, California, Forenede Stater, 91007
- GSK Investigational Site
-
Glendale, California, Forenede Stater, 91206
- GSK Investigational Site
-
Laguna Hills, California, Forenede Stater, 92653
- GSK Investigational Site
-
Pasadena, California, Forenede Stater, 91105
- GSK Investigational Site
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33067
- GSK Investigational Site
-
Melbourne, Florida, Forenede Stater, 32901
- GSK Investigational Site
-
Miami, Florida, Forenede Stater, 33143
- GSK Investigational Site
-
West Palm Beach, Florida, Forenede Stater, 33409
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21229-5299
- GSK Investigational Site
-
-
Michigan
-
Royal Oak, Michigan, Forenede Stater, 48073
- GSK Investigational Site
-
-
New York
-
Mineola, New York, Forenede Stater, 11501
- GSK Investigational Site
-
New Hyde Park, New York, Forenede Stater, 11040
- GSK Investigational Site
-
New York, New York, Forenede Stater, 10038
- GSK Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27103
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45208
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- GSK Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- GSK Investigational Site
-
Winchester, Virginia, Forenede Stater, 22601
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- GSK Investigational Site
-
-
-
-
-
Kwun Tong, Hong Kong
- GSK Investigational Site
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, New Territories, Hong Kong
- GSK Investigational Site
-
Sheung Shui, New Territories, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Lahore, Pakistan
- GSK Investigational Site
-
-
-
-
-
Badalona, Spanien, 08916
- GSK Investigational Site
-
Barcelona, Spanien, 08025
- GSK Investigational Site
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Barcelona, Spanien, 08003
- GSK Investigational Site
-
La Coruña, Spanien, 15006
- GSK Investigational Site
-
Mataro, Spanien, 08034
- GSK Investigational Site
-
Pamplona, Spanien, 31008
- GSK Investigational Site
-
Santiago de Compostela, Spanien, 15706
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand
- GSK Investigational Site
-
-
-
-
-
Brno, Tjekkiet, 625 00
- GSK Investigational Site
-
Jihlava, Tjekkiet, 586 01
- GSK Investigational Site
-
Olomouc, Tjekkiet, 775 20
- GSK Investigational Site
-
Pardubice, Tjekkiet, 532 03
- GSK Investigational Site
-
Praha 2, Tjekkiet, 128 51
- GSK Investigational Site
-
Praha 5, Tjekkiet, 150 08
- GSK Investigational Site
-
-
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Tyskland, 79110
- GSK Investigational Site
-
-
Hessen
-
Marburg, Hessen, Tyskland, 35043
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Neubrandenburg, Mecklenburg-Vorpommern, Tyskland, 17036
- GSK Investigational Site
-
Rostock, Mecklenburg-Vorpommern, Tyskland, 18059
- GSK Investigational Site
-
Schwerin, Mecklenburg-Vorpommern, Tyskland, 19055
- GSK Investigational Site
-
Wismar, Mecklenburg-Vorpommern, Tyskland, 23966
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Ludwigshafen, Rheinland-Pfalz, Tyskland, 67063
- GSK Investigational Site
-
-
Saarland
-
Homburg, Saarland, Tyskland, 66421
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Tyskland, 06120
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Tyskland, 24105
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- History of PONV (postoperative nausea and vomiting) and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain abdominal, breast, thyroid or shoulder surgery.
Exclusion criteria:
- Pregnant or breastfeeding.
- Have certain pre-existing medical conditions or take certain medications.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants who achieved a complete response
Tidsramme: Up to 24 hours
|
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple.
Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose.
Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves").
Study participants who receive antiemetic rescue medication(s) during the initial 24 hours was considered treatment failures.
|
Up to 24 hours
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"
Tidsramme: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a Likert scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
The Likert scale used a range of 0-10, where 0 = no nausea and 10 = nausea as bad as it could be.
|
Up to 48 hours
|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol
Tidsramme: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a categorical scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
In the categorical scale, each participant asked to rate the severity of nausea as, none: no nausea, mild: queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit (but not vomiting), that has a significant negative effect on daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others), severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities.
|
Up to 48 hours
|
|
Number of participants with first emetic event
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with first antiemetic rescue medication
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with chemistry data outside the reference range
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with hematology data outside the reference range
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)
Tidsramme: Up to 24 hours
|
Up to 24 hours
|
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: Up to Days 6-14 visit
|
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use.
The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.
Refer to the general AE/SAE module for a list of AEs and SAEs.
|
Up to Days 6-14 visit
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Postoperative komplikationer
- Tegn og symptomer, fordøjelsessystemet
- Kvalme
- Opkastning
- Postoperativ kvalme og opkastning
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystem
- Antiemetika
- Gastrointestinale midler
- Neurokinin-1-receptorantagonister
- Casopitant
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NKT102552
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Studiedata/dokumenter
-
Datasætspecifikation
Informations-id: NKT102552Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Individuelt deltagerdatasæt
Informations-id: NKT102552Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Annoteret sagsbetænkningsformular
Informations-id: NKT102552Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Formular til informeret samtykke
Informations-id: NKT102552Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokol
Informations-id: NKT102552Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk undersøgelsesrapport
Informations-id: NKT102552Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisk analyseplan
Informations-id: NKT102552Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .